Trends in the Treatment of Cutaneous T-Cell Lymphoma &Ndash; Critical Evaluation and Perspectives on Vorinostat

Blood and Lymphatic Cancer: Targets and Therapy
doi 10.2147/blctt.s15564
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Benefits of Vorinostat in Treating Advanced Cutaneous T-Cell Lymphoma

Oncology & Hematology Review (US)
2009English

Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma

Archives of Dermatology
2009English

Vorinostat Approved in Japan for Treatment of Cutaneous T-Cell Lymphomas: Status and Prospects

OncoTargets and Therapy
OncologyPharmacology
2012English

Treatment of Cutaneous T-Cell Lymphoma: An Update

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1993English

Pcn350 - Evaluation of Disease-Specific Skin Symptom Items on Skindex-29 in Cutaneous T-Cell Lymphoma Patients Treated With Mogamulizumab or Vorinostat

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Orphan Designation: Mogamulizumab, Treatment of Cutaneous T-Cell Lymphoma

Case Medical Research
2019English

676 Exploring Novel Therapeutic Targets in the Treatment of Cutaneous T-Cell Lymphoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Cutaneous T Cell Lymphoma (Mycosis Fungoides)

JMS SKIMS
2010English

Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Medical Journal Armed Forces India
Medicine
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy